Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Novocure Partners With Verastem Oncology on Pancreatic Cancer Trial

By Public Technologies
  • Novocure entered a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate a combination treatment for locally advanced pancreatic cancer.
  • The trial will combine Tumor Treating Fields therapy with chemotherapy and VS-7375, Verastem's investigational oral KRAS G12D inhibitor.
  • Enrollment is expected to begin in 2027, targeting approximately 25 patients.
  • Researchers will assess safety and tolerability, with preliminary efficacy evaluated as exploratory endpoints.
  • Under the agreement, Novocure will manage and fund trial operations; Verastem will supply VS-7375.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610280700BIZWIRE_USPR_____20261028_BW077167) on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.